The coronavirus disease 2019 (COVID-19) has significantly changed the health-care system. COVID-19 patients with comorbidities are more likely to have severe disease, often leading to death. As one primary concern in this pandemic era, glioma patients have an incidence of 30%. It has a high mortality rate. Glioma has multiple comorbidities, at risk of contracting COVID-19, such as elderly, taking high-dose steroid therapy with adjuvant radiotherapy (RT) and chemotherapy. An algorithm for patient-doctor communication, inpatient-outpatient selection, and treatment goals in glioma patients should be carefully made according to local preparation for COVID-19. Surgery, RT, and chemotherapy should be tailored individually to increase survival rate, quality of life, and reduce the risk of COVID-19 exposure. All communication between the health-care provider and patient will be using telemedicine. The patient who requires to visit the inpatient ward will be carefully selected. Asymptomatic glioma or with no progressivity of the disease should have the treatment postponed. Symptomatic high-grade glioma patients with progressive neurological deficits and increased intracranial pressure will be treated with COVID-19 protocols. Surgery, RT, and chemotherapy, especially Temozolomide, will be given after evaluating the patient’s age, Karnofsky Performance Scale (KPS) Score, and molecular finding of O6-methylguanine DNA methyltransferase (MGMT), isocitrate dehydrogenase, and gene 1p/9q. Therefore, it is necessary to have a modified algorithm for glioma patients during this pandemic. Key Messages: A strategy to minimize hospital contact for glioma patients in a pandemic crisis while not delaying their diagnostics and treatments

Rationale: Neurocysticercosis is a neglected tropical disease caused by the larvae of Taenia solium and may occur in immunocompetent people. We report a case of diffuse parenchymal neurocysticercosis mimicking tuberculous meningitis in an immunocompetent patient. Patient concerns: A 24-year-old immunocompetent woman presented with serial focal to generalized seizure, left body weakness, left abducens palsy, chronic cough, and body weight loss. She came from an area where she was unlikely to have contact with Taenia solium. Diagnosis: Diffuse parenchymal neurocysticercosis. Intervention: Valproic acid, dexamethasone and 15 months of albendazole therapy. Outcome: Complete recovery without any neurological sequelae. Lessons: Prolonged anthelminthic treatment may benefit neurocysticercosis patients with multiple cerebral parenchymal lesions.

No abstract

No abstract

Introduction: Indonesia has the most dengue outbreaks in the ASEAN region. Lack of diagnostic modality and poor sanitation especially in rural area hinders proper and prompt management of Dengue Fever. Aim: Finding the early, simple, and reliable predictor of Dengue Shock Syndrome (DSS) in Indonesia. Materials and Methods: A retrospective study reviewing the medical record of pediatric patient with dengue infection from 1 January 2016 to 31 March 2016 were conducted. Age, gender, dengue signs, and simple laboratory result were collected. The data acquired were then analyzed using logistic regression for multivariate analysis (P<0,05) to find the severity predictor. Results: 80 cases of dengue infection were included, mean age was 7,7 ± 3.4 years old, the average length of hospital stay was 4.59 days. 28.75% of patients had DSS. From the multivariate analysis, it is found that lethargy (p= 0.00; OR 21.23), bleeding (p= 0.01; OR 0,04), cold extremities (p=0.00;OR=22.35), and increased haematocrit level (p=0.01;OR=4.72) has significant relationship with DSS while other indicator did not. Conclusion: Patients presenting with lethargy, cold extremities, and increase in haematocrit level should be treated promptly and intensively as they are more likely to develop DSS compared to patients who did not.